PRESS RELEASE published on 09/13/2023 at 14:30, 2 years 4 months ago Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
PRESS RELEASE published on 09/12/2023 at 14:30, 2 years 4 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 09/11/2023 at 14:30, 2 years 4 months ago Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
PRESS RELEASE published on 09/07/2023 at 14:30, 2 years 4 months ago Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
PRESS RELEASE published on 08/30/2023 at 14:30, 2 years 5 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 2 years 5 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 2 years 5 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 2 years 5 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 2 years 5 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
PRESS RELEASE published on 08/14/2023 at 14:00, 2 years 5 months ago Jaguar Health Reports Second Quarter 2023 Financial Results
Published on 01/30/2026 at 14:00, 3 hours 19 minutes ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 8 hours 44 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 9 hours 19 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 15 hours 4 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 17 hours 19 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/30/2026 at 16:46, 33 minutes ago Custodian Property Income REIT plc: Investor Presentation via Investor Meet Company
Published on 01/30/2026 at 16:00, 1 hour 19 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/29/2026 at 18:00, 23 hours 19 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 23 hours 34 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 23 hours 34 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
